Lakewood-Amedex releases investor deck on Bisphosphocin platform and Nu-3 gel for diabetic foot ulcers

Lakewood-Amedex Biotherapeutics Inc.

Investor deck highlights Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials.
Lead program Nu-3 is a topically delivered antimicrobial gel for infected diabetic foot ulcers (iDFU).
Deck includes preclinical/clinical data, regulatory strategy, intellectual property, and competitive landscape.
Presentation is for use in meetings with investors, analysts, and third parties; no material financial updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.